177 related articles for article (PubMed ID: 34817046)
1. RNA-binding protein with serine-rich domain 1 regulates microsatellite instability of uterine corpus endometrial adenocarcinoma.
Liu X; Ma H; Ma L; Li K; Kang Y
Clinics (Sao Paulo); 2021; 76():e3318. PubMed ID: 34817046
[TBL] [Abstract][Full Text] [Related]
2. The potential role of methyltransferase-like 5 in deficient mismatch repair of uterine corpus endometrial carcinoma.
Liu X; Ma H; Ma L; Li K; Kang Y
Bioengineered; 2022 Mar; 13(3):5525-5536. PubMed ID: 35166644
[TBL] [Abstract][Full Text] [Related]
3. Frequent CTNNB1 or PIK3CA Mutations Occurred in Endometrial Endometrioid Adenocarcinoma With High Levels of Microsatellite Instability and Loss of MSH2/MSH6 Expression.
Huang HN; Kuo CW; Lin MC; Mao TL; Kuo KT
Appl Immunohistochem Mol Morphol; 2020 Apr; 28(4):284-289. PubMed ID: 30789355
[TBL] [Abstract][Full Text] [Related]
4. Endometrial carcinomas in women aged 40 years and younger: tumors associated with loss of DNA mismatch repair proteins comprise a distinct clinicopathologic subset.
Garg K; Shih K; Barakat R; Zhou Q; Iasonos A; Soslow RA
Am J Surg Pathol; 2009 Dec; 33(12):1869-77. PubMed ID: 19898223
[TBL] [Abstract][Full Text] [Related]
5. Ovarian endometrioid adenocarcinoma: incidence and clinical significance of the morphologic and immunohistochemical markers of mismatch repair protein defects and tumor microsatellite instability.
Aysal A; Karnezis A; Medhi I; Grenert JP; Zaloudek CJ; Rabban JT
Am J Surg Pathol; 2012 Feb; 36(2):163-72. PubMed ID: 22189970
[TBL] [Abstract][Full Text] [Related]
6. Discordant loss of mismatch repair proteins in advanced endometrial endometrioid carcinoma compared to paired primary uterine tumors.
Ta RM; Hecht JL; Lin DI
Gynecol Oncol; 2018 Dec; 151(3):401-406. PubMed ID: 30340772
[TBL] [Abstract][Full Text] [Related]
7. Long non‑coding RNA BLACAT2/miR‑378a‑3p/YY1 feedback loop promotes the proliferation, migration and invasion of uterine corpus endometrial carcinoma.
Zhang C; Wang R; Li M; Yang Q
Oncol Rep; 2023 May; 49(5):. PubMed ID: 37052291
[TBL] [Abstract][Full Text] [Related]
8. MCM10: An effective treatment target and a prognostic biomarker in patients with uterine corpus endometrial carcinoma.
Chen J; Wu S; Wang J; Han C; Zhao L; He K; Jia Y; Cui M
J Cell Mol Med; 2023 Jun; 27(12):1708-1724. PubMed ID: 37246638
[TBL] [Abstract][Full Text] [Related]
9.
Zhao Q; Chen G; Yang X; Wang T; Yuan S; Meng Q
Comb Chem High Throughput Screen; 2023; 26(2):330-338. PubMed ID: 35379118
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of PSAT1 inhibits cell proliferation and migration in uterine corpus endometrial carcinoma.
Wang M; Yue S; Yang Z
Sci Rep; 2023 Mar; 13(1):4081. PubMed ID: 36906716
[TBL] [Abstract][Full Text] [Related]
11. LHX1 as a potential biomarker regulates EMT induction and cellular behaviors in uterine corpus endometrial carcinoma.
Tian Y; Wen F; Wang S; Lv N
Clinics (Sao Paulo); 2022; 77():100103. PubMed ID: 36116266
[TBL] [Abstract][Full Text] [Related]
12. [Expression and clinical significance of MMR protein and MLH1 promoter methylation testing in endometrial cancer].
Jin W; Wang LQ; Liu Y; Liu AJ
Zhonghua Fu Chan Ke Za Zhi; 2018 Dec; 53(12):823-830. PubMed ID: 30585020
[No Abstract] [Full Text] [Related]
13. GNA14 stimulation of KLF7 promotes malignant growth of endometrial cancer through upregulation of HAS2.
Wang J; Teng F; Chai H; Zhang C; Liang X; Yang Y
BMC Cancer; 2021 Apr; 21(1):456. PubMed ID: 33892667
[TBL] [Abstract][Full Text] [Related]
14. KDM4B, a potential prognostic biomarker revealed by large-scale public databases and clinical samples in uterine corpus endometrial carcinoma.
Zhang M; Liu Y; Hou S; Wang Y; Wang C; Yin Y; Chen X
Mol Omics; 2022 Jul; 18(6):506-519. PubMed ID: 35485290
[TBL] [Abstract][Full Text] [Related]
15. PHF6 promotes the progression of endometrial carcinoma by increasing cancer cells growth and decreasing T-cell infiltration.
Wang X; Fang A; Peng Y; Yu J; Yu C; Xie J; Zheng Y; Song L; Li P; Li J; Kang X; Lin Y; Li W
J Cell Mol Med; 2023 Mar; 27(5):609-621. PubMed ID: 36756714
[TBL] [Abstract][Full Text] [Related]
16. Exploring the role of PRDX4 in the development of uterine corpus endometrial carcinoma.
Lei P; Yu L; Sun X; Hao J; Shi W; Sun H; Guo X; Jia X; Liu T; Zhang DL; Li L; Wang H; Xu C
Med Oncol; 2024 Jan; 41(2):48. PubMed ID: 38177789
[TBL] [Abstract][Full Text] [Related]
17. FAT2 mutation is associated with better prognosis and responsiveness to immunotherapy in uterine corpus endometrial carcinoma.
Wang Z; Xing L; Huang Y; Han P
Cancer Med; 2023 Feb; 12(3):3797-3811. PubMed ID: 36812126
[TBL] [Abstract][Full Text] [Related]
18. RNPS1 functions as an oncogenic splicing factor in cervical cancer cells.
Deka B; Chandra P; Yadav P; Rehman A; Kumari S; Kunnumakkara AB; Singh KK
IUBMB Life; 2023 Jun; 75(6):514-529. PubMed ID: 36300671
[TBL] [Abstract][Full Text] [Related]
19. A Five-microRNA Signature as Risk Stratification System in Uterine Corpus Endometrial Carcinoma.
Chen Z; Huang X; Lv Y; Fang Y; Pan L; Gan Z; Huang Z; Wei W
Comb Chem High Throughput Screen; 2021; 24(2):187-194. PubMed ID: 32748742
[TBL] [Abstract][Full Text] [Related]
20. Medical Significance of Uterine Corpus Endometrial Carcinoma Patients Infected With SARS-CoV-2 and Pharmacological Characteristics of Plumbagin.
Li Y; Yu S; Li Y; Liang X; Su M; Li R
Front Endocrinol (Lausanne); 2021; 12():714909. PubMed ID: 34712201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
